DIVISLAB — Divi's Laboratories Balance Sheet
0.000.00%
- IN₹1.60tn
- IN₹1.56tn
- IN₹78.45bn
Annual balance sheet for Divi's Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 10,145 | 20,303 | 12,148 | 1,697 | 3,630 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 16,812 | 18,198 | 25,896 | 20,372 | 23,950 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 46,798 | 61,747 | 83,515 | 93,117 | 96,750 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 36,979 | 44,095 | 47,875 | 49,292 | 55,130 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 85,357 | 107,741 | 133,747 | 144,388 | 154,700 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9,268 | 11,125 | 11,956 | 11,011 | 12,780 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 12,258 | 14,795 | 16,465 | 16,717 | 18,990 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 73,099 | 92,946 | 117,282 | 127,671 | 135,710 |
Total Liabilities & Shareholders' Equity | 85,357 | 107,741 | 133,747 | 144,388 | 154,700 |
Total Common Shares Outstanding |